Clare Arnott's Publications

About Clare Arnott's Publications

Global Director, Cardiovascular Program
  • Co-Director, Global Chronic & Complex Diseases
  • BMed Sci,
  • MBBS (Hons),
  • PhD,
  • FRACP,
  • FESC,
  • CF

  • Contemporary epidemiology of hospitalised heart failure with reduced versus preserved ejection fraction in England: a retrospective, cohort study of whole-population electronic health records

    The Lancet Public Health Date published:

  • Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes

    Journal of the American College of Cardiology Date published:

  • Modern epidemiology of heart failure with reduced and preserved ejection fraction in population-wide linked electronic health records: a study of 208815 heart failure patients in England

    European Heart Journal Date published:

  • Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: a participant level pooled analysis of CREDENCE and CANVAS

    European Heart Journal Date published:

  • Bidirectional relationship between kidney disease progression and cardiovascular events in type 2 diabetes: new Insights from the CANVAS Program and CREDENCE trial

    European Heart Journal Date published:

  • Optimizing Clinical Outcomes Beyond Heart Failure With Intravenous Iron

    Journal of the American College of Cardiology Date published:

  • Canagliflozin and iron metabolism in the CREDENCE trial

    Nephrology Dialysis Transplantation Date published:

  • Risk of Cardiovascular Disease in Female Cancer Survivors: A Population Cohort Study Using Linked Australian Health Datasets

    Heart, Lung and Circulation Date published:

  • An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes

    Diabetes, Obesity and Metabolism Date published:

  • Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial

    European Journal of Heart Failure Date published:

  • Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial

    Diabetes, Obesity and Metabolism Date published:

  • Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Secondary Analysis of the Salt Substitute and Stroke Study (SSaSS): Effects of Potassium-Enriched Salt on Cardiac Outcomes

    Hypertension Date published:

  • Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD

    Clinical Journal of the American Society of Nephrology Date published:

  • Prediction of new-onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS

    Diabetes, Obesity and Metabolism Date published:

  • Knowledge, attitudes, and behaviors related to dietary salt intake and the acceptability of salt substitute among the Australian culturally and linguistically diverse community: An online survey

    The Journal of Clinical Hypertension Date published: